Last reviewed · How we verify
Bioimpedance analysis
Bioimpedance analysis measures electrical impedance across body tissues to assess body composition and fluid distribution.
Bioimpedance analysis measures electrical impedance across body tissues to assess body composition and fluid distribution. Used for Assessment of body composition and fluid status in clinical populations, Monitoring fluid overload in heart failure and renal disease patients, Nutritional assessment and monitoring.
At a glance
| Generic name | Bioimpedance analysis |
|---|---|
| Sponsor | University Hospital, Clermont-Ferrand |
| Modality | Small molecule |
| Therapeutic area | Diagnostics / Monitoring |
| Phase | FDA-approved |
Mechanism of action
This is a non-invasive diagnostic technique that applies small electrical currents to the body and measures resistance to determine total body water, intracellular and extracellular fluid volumes, and lean body mass. It is used clinically to monitor fluid status in conditions like heart failure, renal disease, and malnutrition, as well as to assess body composition changes.
Approved indications
- Assessment of body composition and fluid status in clinical populations
- Monitoring fluid overload in heart failure and renal disease patients
- Nutritional assessment and monitoring
Common side effects
Key clinical trials
- The Prevalance of Malnutrition and Its Association With Disability in Patients With Relapsing-Remitting Multiple Sclerosis
- Incidence of Liver Disease-Related Outcomes in People With HIV
- The Influence of Non-Caloric Artificial Sweeteners on Youth With Type 1 Diabetes
- Acute Sarcopenia in Hospitalized Older Adults
- Adherence to an Exercise Program and Pre- and Post-Changes After Bariatric Surgery (NA)
- Multidimensional Predictors of Balance in Healthy Young Adults
- Investigation of the Relationship Between Gray and White Matter Volumes, Walking Exercise, and Body Fat Percentage in Adults With a Body Mass Index Above 25 (NA)
- Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bioimpedance analysis CI brief — competitive landscape report
- Bioimpedance analysis updates RSS · CI watch RSS
- University Hospital, Clermont-Ferrand portfolio CI